KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Other Accumulated Expenses (2018 - 2025)

Amneal Pharmaceuticals (AMRX) has 7 years of Other Accumulated Expenses data on record, last reported at $43.3 million in Q4 2025.

  • For Q4 2025, Other Accumulated Expenses rose 36.22% year-over-year to $43.3 million; the TTM value through Dec 2025 reached $43.3 million, up 36.22%, while the annual FY2025 figure was $43.3 million, 36.22% up from the prior year.
  • Other Accumulated Expenses reached $43.3 million in Q4 2025 per AMRX's latest filing, up from $40.6 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $275.3 million in Q2 2022 and bottomed at $30.1 million in Q1 2024.
  • Average Other Accumulated Expenses over 5 years is $76.0 million, with a median of $50.8 million recorded in 2021.
  • Peak YoY movement for Other Accumulated Expenses: surged 85.32% in 2022, then tumbled 72.03% in 2023.
  • A 5-year view of Other Accumulated Expenses shows it stood at $58.0 million in 2021, then soared by 85.32% to $107.5 million in 2022, then dropped by 28.37% to $77.0 million in 2023, then tumbled by 58.75% to $31.8 million in 2024, then skyrocketed by 36.22% to $43.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $43.3 million in Q4 2025, $40.6 million in Q3 2025, and $41.5 million in Q2 2025.